Aurinia Pharmaceuticals (AUPH)
Markets LUPKYNIS for lupus nephritis and develops additional autoimmune therapies.
$16.29
Pre-market−0.01 (−0.06%)
At close$16.30(+1.56%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 55 | 45 | 50 | 57 | 68 | 60 | 62 | 70 | 73 | 77 | 78 | 83 |
| Cost of revenue | 7 | 5 | 8 | 9 | 6 | 6 | 9 | 7 | 9 | 8 | 7 | 7 |
| Gross profit | 48 | 40 | 43 | 48 | 62 | 54 | 54 | 63 | 65 | 69 | 71 | 77 |
| 64 | 69 | 53 | 50 | 50 | 56 | 32 | 43 | 35 | 35 | 30 | 30 | |
| Research & development | 14 | 10 | 6 | 4 | 3 | 8 | 6 | 7 | 8 | 11 | 7 | 13 |
| 48 | 50 | 48 | 45 | 42 | 45 | 20 | 26 | 26 | 29 | 22 | 24 | |
| Selling & marketing | 0 | 0 | 3 | 4 | 5 | 14 | 1 | 1 | 1 | 1 | 0 | 0 |
| General & administrative | 48 | 50 | 44 | 41 | 38 | 31 | 19 | 25 | 26 | 28 | 22 | 24 |
| Other expenses | 3 | 9 | 0 | 1 | 5 | 3 | 6 | 9 | 1 | −5 | 0 | −6 |
| Operating income | −16 | −30 | −11 | −2 | 12 | −2 | 22 | 20 | 30 | 33 | 41 | 46 |
| 3 | 3 | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 2 | |
| Interest income | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 3 | 2 | 5 | 4 | 3 |
| Interest expense | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 7 | 1 | 1 |
| Other non-operating income | −5 | −5 | −2 | −4 | −4 | −4 | −4 | −3 | −2 | −9 | −4 | −3 |
| Income before tax | −13 | −26 | −10 | 1 | 15 | 1 | 24 | 22 | 32 | 36 | 44 | 49 |
| Income tax expense | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | −175 | 10 | 11 |
| Net income from continuing operations | −13 | −27 | −11 | 1 | 14 | 1 | 23 | 22 | 32 | 211 | 34 | 37 |
| Net income | −13 | −27 | −11 | 1 | 14 | 1 | 23 | 22 | 32 | 211 | 34 | 37 |
| EPS, basic | −$0.09 | −$0.19 | −$0.07 | $0.01 | $0.10 | $0.01 | $0.16 | $0.16 | $0.23 | $1.58 | $0.26 | $0.29 |
| EPS, diluted | −$0.09 | −$0.19 | −$0.07 | $0.01 | $0.10 | $0.01 | $0.16 | $0.15 | $0.23 | $1.53 | $0.25 | $0.28 |
| Weighted average shares, basic | 143 | 144 | 144 | 143 | 143 | 142 | 139 | 139 | 136 | 134 | 132 | 130 |
| Weighted average shares, diluted | 143 | 144 | 144 | 144 | 146 | 148 | 139 | 143 | 136 | 139 | 138 | 134 |
| EBITDA | −6 | −20 | −4 | 8 | 21 | 7 | 30 | 28 | 37 | 47 | 50 | 55 |
| Depreciation & amortization | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| EBIT | −12 | −25 | −9 | 3 | 16 | 2 | 25 | 23 | 32 | 42 | 45 | 50 |